PathoVax

PathoVax LLC is pleased to have a presence back in Boston as part of the family at . We are also very pleased to be alongside fellow Singaporean Company 🇸🇬🇺🇸

Two pieces of great news this Mid-March! First off, PathoVax has secured another SBIR Phase 1 worth $300K from the NCI to imbue thermostable and single-dose properties into our existing RGVax HPV vaccine. This new formulation will potentiate the world’s 1st single- immunization, thermostable, broad-spectrum Human Papillomavirus (HPV) Vaccine!!

Secondly, We will be presenting long term pre-clinical protection data in a Late Breaking Abstract Poster session at the upcoming 2019 American Association for Cancer Research Annual Meeting!!!

1st Annual PathoVax Christmas Party! Special thanks to our Scientific Advisor, Prof Roden for joining us!!! ! Happy Holidays to all!!!

PathoVax closes $2.75M Series A1 round!

JHU startup PathoVax raises $2.75M, grows team - Technical.ly Baltimore The company is working toward clinical trials of its HPV vaccine.

UPDATE: Catch all our talks/posters at the IPVC conference! .

4th Oct 1300-1400, Exhibition Area, Session code: PS10
Speaker: Prof Reinhard Kirnbauer, Scientific Advisor, Inventor of RGVax
Title: THERMOSTABILIZATION OF RG1-VLPS, A BROAD-SPECTRUM HPV VACCINE CANDIDATE

4th Oct, 15:45, Room C4.9, Session code: RC02
Speaker: Joshua Wang, Co-Founder
Presentation Title: cGMP PRODUCTION OF A MONOVALENT CHIMERIC PAPILLOMAVIRUS VACCINE (HPV16 RG-1VLP) CONFERS CROSS PROTECTION AGAINST DISEASE EQUIVALENT TO TYPE-SPECIFIC LICENSED L1-VLP VACCINES IN PAPILLOMAVIRUS ANIMAL MODELS

6th October, 12:35, Room C4.9, Session code: SSS07
Speaker: Prof Richard Roden, Scientific Advisor, Inventor of RGVax
Presentation Title: ROLES OF FC DOMAIN AND EXUDATION IN L2 ANTIBODY-MEDIATED PROTECTION AGAINST HUMAN PAPILLOMAVIRUS

===============
PathoVax's late-breaking abstract has been accepted for an ORAL PRESENTATION during the 32nd International Papillomavirus Conference held at Sydney, Australia from October 2-6, 2018.

Looking forward to presenting our RGVax vaccine data demonstrating complete cross-protection against several HPVs!

32nd IPVC Conference Join us at IPVC for an outstanding program of invited lectures, oral abstract sessions, poster sessions, symposia, workshops and social events in magical Sydney!

Expanding our global outreach! We are pleased to announce that PathoVax is a 2018 Laureate in the YEi initiative program. This provides a personalized immersion week in France (including training sessions, networking and one-on-one meetings) that will allow us to benefit from an extensive customized business network and connections to the best resources in Europe.

Meet the 2018 US Laureates of the YEi Start in France Program - Office for Science & Technology of the Embassy of France in the United States The YEi Start in France program is an annual competition organized by the Ministry for Europe and Foreign Affairs for young foreign science-based companies interested in growing their business in France and Europe. Meet the 2018 US Laureates of the YEI Start in France Program.

Happy 4th of July! As fireworks light up the sky to celebrate Independence Day! We are celebrating our own brand new independent lab space !

In addition to the US$30k First Place prize award, PathoVax received a fully-sponsored networking trip to six major cities in China (Beijing, Shandong, Shanghai, Hefei, Hangzhou and Guangzhou) from July-20 to August-5. Get in touch if you are interested to learn more about the first universal HPV vaccine!

The 4th annual China-US Innovation Competition hosted by the Entrepreneur Foundation BOSTON, June 6, 2018 /PRNewswire/ -- On April 22, 2018, the 4th annual China-US Innovation Competition hosted by...

We are honored to have received 1st Place ($100K RMB) at the 2nd China (Shenzhen) Innovation & Entrepreneurship International Competition (Boston, USA division)! Looking forward to having Weijie Poh represent us and share our vision of preventing and treating Cancers/infectious diseases at the grand finals in Shenzhen, China! #全面保护 #加油!!!!

Today marks the last day of our tenure as alum-in-residence at the Harvard Innovation Labs. Thanks for housing us during our early days in Boston and accelerating our growth in this amazing ecosystem!

Proud feature in the Baltimore Business Journal. We hope to bring this positive momentum into 2018!

updated with article link! http://bizj.us/1phbiq

Hopkins-born startup PathoVax wins $2.5 million, nears clinical trial readiness - Baltimore Business Journal The grants came through the National Institute of Allergy and Infectious Diseases and the National Science Foundation.

Christmas comes early for PathoVax this year!

Following our STTR award in September by the National Cancer Institute (NCI), we are pleased to announce that PathoVax has been awarded TWO more SBIR grants ($2.3M USD in total) from the National Institute of Allergy and Infectious Diseases (NIAID) as well as the National Science Foundation (NSF) to advance our Human Papillomavirus Virus-like particles for both infectious diseases and cancer!!

These grants will fund activities associated with filing an Investigational New Drug (IND) application with the FDA for PathoVax's lead product candidate as well as continue our research in using our HPV VLPs for therapeutic purposes!